Treats urinary tract infections. ANDA 217272, held by Mankind Pharma. Nitrofurantoin, Macrocrystalline.
As of Nov 16, 2026, ANDA 217272 (Nitrofurantoin), held by Mankind Pharma, was first approved by FDA on Mar 21, 2023, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Nitrofurantoin capsules (macrocrystals) are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 21, 2023 | Original application | Approved | None posted |
| Nitrofurantoin25MG · capsule;oral | Nitrofurantoin, Macrocrystalline | Rx |
| Nitrofurantoin50MG · capsule;oral | Nitrofurantoin, Macrocrystalline | Rx |
| Nitrofurantoin100MG · capsule;oral | Nitrofurantoin, Macrocrystalline | Rx |
| Mar 21, 2025 | Supplement 4Manufacturing | Approved | None posted |
| Mar 21, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters